A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs BIO-11006 (Primary)
- Indications Respiratory distress syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors BioMarck Pharmaceuticals
- 02 Oct 2017 Status changed from not yet recruiting to recruiting.
- 27 Jun 2017 Status changed from planning to not yet recruiting.
- 20 Jan 2016 New trial record